BridgeMD
New treatment option for ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Official title Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ClinicalTrials.gov ID: NCT06800651
What this study is testing
What is JMKX003142 will be administered orally?
JMKX003142 will be administered orally is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for adpkd (autosomal dominant polycystic kidney disease).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- Able to understand the procedures of this trial and provide written informed consent voluntarily;
- Age between 18 to 55 years, male or female;
- ADPKD diagnostic criteria were met before randomization;
- Rapidly progressive ADPKD criteria were met.
You likely can't join if
- 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely...
- Praticipants who are unable to feel thirst, or have difficulty with fluid/food intake;
- Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF;
- The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.